Medullary thyroid cancer

What changed: Medullary thyroid cancer

Cancer page →

Every dated change on the records linked to Medullary thyroid cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Approval4Regulatory2Milestone6This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordMedullary thyroid cancer
Facts on this page last checked
When this page itself was last checked or edited.

2023 · 1

2023MilestoneSelpercatinib
LIBRETTO-531: selpercatinib beats the multikinase drugs first line
A milestone in how this cancer is treated.

May 2020 · 1

2020-05-08RegulatorySelpercatinib
Selpercatinib: approval (US)
Accelerated approval, RET-fusion NSCLC and thyroid cancer, RET-mutant MTC (LIBRETTO-001)

2020 · 2

2014 · 1

2014ApprovalCabozantinib
Cabozantinib approved in EU
Cometriq for medullary thyroid cancer; 21 Mar 2014. Cabometyx (RCC) Sep 2016

2012 · 2

April 2011 · 1

2011-04-06RegulatoryVandetanib
Vandetanib: approval (US)
First approval for medullary thyroid cancer

2011 · 2

1993 · 1

1993MilestoneRET
RET mutations found to cause MEN2
A milestone in how this cancer is treated.

1959 · 1

1959MilestoneMedullary thyroid cancer
Hazard describes medullary thyroid carcinoma as a distinct tumour
A milestone in how this cancer is treated.